公开(公告)号：US20160302731A1

公开(公告)日：2016-10-20

申请号：US15197349

申请日：2016-06-29

Applicant: DexCom, Inc.

Inventor： Paul V. Goode ,  James H. Brauker ,  Arpurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

IPC: A61B5/00 ,  A61B5/1473 ,  A61B5/145

CPC classification number: A61B5/7203 ,  A61B5/0004 ,  A61B5/0031 ,  A61B5/14532 ,  A61B5/14539 ,  A61B5/14542 ,  A61B5/1473 ,  A61B5/14865 ,  A61B5/1495 ,  A61B5/7225 ,  A61B5/7257 ,  A61B5/726 ,  A61B5/7278 ,  A61B5/742 ,  A61B5/7475 ,  A61B2560/0223 ,  A61B2562/0247 ,  A61B2562/0271 ,  A61B2562/08

Abstract: Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.

Abstract translation: 用于最小化或消除由于非葡萄糖速率限制现象（如缺血，pH变化，温度变化等）引起的瞬时非葡萄糖相关信号噪声的系统和方法。 系统监测来自葡萄糖传感器的数据流，并检测具有比电子或扩散相关系统噪声更高的幅度的信号伪像。 该系统连续地或间歇地替代一些或整个数据流，包括特别地解决瞬态信号伪影的信号估计方法。 该系统还能够检测信号伪像的严重性并且响应于信号伪像的严重性选择性地应用一个或多个信号估计算法因子，其包括选择性地将不同的参数集合应用于信号估计算法或选择性地应用不同信号 估计算法。

公开(公告)号：US20230293056A1

公开(公告)日：2023-09-21

申请号：US18126236

申请日：2023-03-24

Applicant: Dexcom, Inc.

Inventor： James H. Brauker ,  Victoria Carr-Brendel ,  Paul Goode ,  Apurv U. Kamath ,  James Patrick Thrower ,  Ben Xavier

IPC: A61B5/145 ,  A61B5/1468 ,  A61B5/1486 ,  A61B5/1495 ,  A61B5/00 ,  G16Z99/00 ,  A61M5/172

CPC classification number: A61B5/14532 ,  A61B5/1468 ,  A61B5/1486 ,  A61B5/1495 ,  A61B5/7257 ,  A61B5/726 ,  G16Z99/00 ,  A61B5/145 ,  A61B5/742 ,  A61B5/746 ,  A61M5/1723 ,  A61B5/14503 ,  A61B5/1451 ,  A61B5/7264 ,  A61B5/7275 ,  A61B5/7455 ,  A61B5/7475 ,  A61B5/14865 ,  Y02A90/10 ,  A61B5/1473

Abstract: Systems and methods for dynamically and intelligently estimating analyte data from a continuous analyte sensor, including receiving a data stream, selecting one of a plurality of algorithms, and employing the selected algorithm to estimate analyte values. Additional data processing includes evaluating the selected estimative algorithms, analyzing a variation of the estimated analyte values based on statistical, clinical, or physiological parameters, comparing the estimated analyte values with corresponding measure analyte values, and providing output to a user. Estimation can be used to compensate for time lag, match sensor data with corresponding reference data, warn of upcoming clinical risk, replace erroneous sensor data signals, and provide more timely analyte information encourage proactive behavior and preempt clinical risk.

公开(公告)号：US20180256084A1

公开(公告)日：2018-09-13

申请号：US15977927

申请日：2018-05-11

Applicant: DexCom, Inc.

Inventor： James R. Petisce ,  Mark A. Tapsak ,  Peter C. Simpson ,  Victoria Carr-Brendel ,  James H. Brauker

IPC: A61B5/1473 ,  A61B5/1486 ,  A61B5/145

CPC classification number: A61B5/1473 ,  A61B5/145 ,  A61B5/14503 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/1468 ,  A61B5/14735 ,  A61B5/14865 ,  C12Q1/002 ,  C12Q1/006

Abstract: The present invention relates generally to systems and methods for increasing oxygen availability to implantable devices. The preferred embodiments provide a membrane system configured to provide protection of the device from the biological environment and/or a catalyst for enabling an enzymatic reaction, wherein the membrane system includes a polymer formed from a high oxygen soluble material. The high oxygen soluble polymer material is disposed adjacent to an oxygen-utilizing source on the implantable device so as to dynamically retain high oxygen availability to the oxygen-utilizing source during oxygen deficits. Membrane systems of the preferred embodiments are useful for implantable devices with oxygen-utilizing sources and/or that function in low oxygen environments, such as enzyme-based electrochemical sensors and cell transplantation devices.

公开(公告)号：US09750460B2

公开(公告)日：2017-09-05

申请号：US15488190

申请日：2017-04-14

Applicant: DexCom, Inc.

Inventor： Paul V. Goode ,  James H. Brauker ,  Arpurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

IPC: A61B5/00 ,  A61B5/05 ,  A61B5/145 ,  A61B5/1486 ,  A61B5/1495

CPC classification number: A61B5/7203 ,  A61B5/0004 ,  A61B5/0031 ,  A61B5/14532 ,  A61B5/14539 ,  A61B5/14542 ,  A61B5/1473 ,  A61B5/14865 ,  A61B5/1495 ,  A61B5/7225 ,  A61B5/7257 ,  A61B5/726 ,  A61B5/7278 ,  A61B5/742 ,  A61B5/7475 ,  A61B2560/0223 ,  A61B2562/0247 ,  A61B2562/0271 ,  A61B2562/08

Abstract: Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.

公开(公告)号：US20170150910A1

公开(公告)日：2017-06-01

申请号：US15429022

申请日：2017-02-09

Applicant: DexCom, Inc.

Inventor： James R. Petisce ,  Mark A. Tapsak ,  Peter C. Simpson ,  Victoria Carr-Brendel ,  James H. Brauker

IPC: A61B5/1473 ,  A61B5/1486 ,  A61B5/145

CPC classification number: A61B5/1473 ,  A61B5/145 ,  A61B5/14503 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/1468 ,  A61B5/14735 ,  A61B5/14865

Abstract: The present invention relates generally to systems and methods for increasing oxygen availability to implantable devices. The preferred embodiments provide a membrane system configured to provide protection of the device from the biological environment and/or a catalyst for enabling an enzymatic reaction, wherein the membrane system includes a polymer formed from a high oxygen soluble material. The high oxygen soluble polymer material is disposed adjacent to an oxygen-utilizing source on the implantable device so as to dynamically retain high oxygen availability to the oxygen-utilizing source during oxygen deficits. Membrane systems of the preferred embodiments are useful for implantable devices with oxygen-utilizing sources and/or that function in low oxygen environments, such as enzyme-based electrochemical sensors and cell transplantation devices.

公开(公告)号：US20140275900A1

公开(公告)日：2014-09-18

申请号：US14290842

申请日：2014-05-29

Applicant: DexCom, Inc.

Inventor： Mark Shults ,  James H. Brauker ,  Victoria Carr-Brendel ,  Mark Tapsak ,  Dubravka Markovic

IPC: A61B5/1486 ,  A61B5/145

CPC classification number: A61B5/14865 ,  A61B5/14532 ,  A61L31/10 ,  A61L31/14 ,  A61L31/146 ,  A61L31/16 ,  A61L2300/00 ,  B33Y80/00 ,  G01N33/48707

Abstract: A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.

Abstract translation: 一种用于可植入装置的生物界面膜，其包括不可再吸收的固体部分，其具有适于在体内支持组织向内生长的多个相互连接的空腔，以及并入生物界面膜中并适于修饰组织反应的生物活性剂。 可以选择生物活性剂以诱导血管形成和/或预防体内阻隔细胞层形成，并且当与其中溶质被输送穿过装置 - 组织界面的可植入装置一起使用时是有利的。

公开(公告)号：US20180296164A1

公开(公告)日：2018-10-18

申请号：US16011414

申请日：2018-06-18

Applicant: DexCom, Inc.

Inventor： Paul V. Goode ,  James H. Brauker ,  Arpurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

IPC: A61B5/00 ,  A61B5/145 ,  A61B5/1495 ,  A61B5/1486 ,  A61B5/1473

Abstract: Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.

公开(公告)号：US09724045B1

公开(公告)日：2017-08-08

申请号：US15481347

申请日：2017-04-06

Applicant: DexCom, Inc.

Inventor： Paul V. Goode, Jr. ,  James H. Brauker ,  Apurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

IPC: A61B5/00 ,  A61B5/145 ,  A61B5/1486 ,  A61B5/1495

CPC classification number: A61B5/7203 ,  A61B5/0004 ,  A61B5/0031 ,  A61B5/14532 ,  A61B5/14539 ,  A61B5/14542 ,  A61B5/1473 ,  A61B5/14865 ,  A61B5/1495 ,  A61B5/7225 ,  A61B5/7257 ,  A61B5/726 ,  A61B5/7278 ,  A61B5/742 ,  A61B5/7475 ,  A61B2560/0223 ,  A61B2562/0247 ,  A61B2562/0271 ,  A61B2562/08

Abstract: Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.

公开(公告)号：US09597027B2

公开(公告)日：2017-03-21

申请号：US14529034

申请日：2014-10-30

Applicant: DexCom, Inc.

Inventor： James R. Petisce ,  Mark A. Tapsak ,  Peter C. Simpson ,  Victoria Carr-Brendel ,  James H. Brauker

IPC: A61B5/1486 ,  A61B5/1468 ,  A61B5/1473 ,  A61B5/145

CPC classification number: A61B5/1473 ,  A61B5/145 ,  A61B5/14503 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/1468 ,  A61B5/14735 ,  A61B5/14865

Abstract: The present invention relates generally to systems and methods for increasing oxygen availability to implantable devices. The preferred embodiments provide a membrane system configured to provide protection of the device from the biological environment and/or a catalyst for enabling an enzymatic reaction, wherein the membrane system includes a polymer formed from a high oxygen soluble material. The high oxygen soluble polymer material is disposed adjacent to an oxygen-utilizing source on the implantable device so as to dynamically retain high oxygen availability to the oxygen-utilizing source during oxygen deficits. Membrane systems of the preferred embodiments are useful for implantable devices with oxygen-utilizing sources and/or that function in low oxygen environments, such as enzyme-based electrochemical sensors and cell transplantation devices.